featured
ESMO 2020: ASCENT Positions Sacituzumab Govitecan as Possible Standard of Care for Previously Treated Metastatic Triple-Negative Breast Cancer
This first-in-class agent is currently being evaluated in other settings
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.